TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04291365

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood pressure measurement
Description: Study subjects will have a total of 9 blood pressure measurements taken (3 on upper arm, 3 on lower arm, and 3 on wrist)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood pressure measurement
Description: Study subjects will have a total of 9 blood pressure measurements taken (3 on upper arm, 3 on lower arm, and 3 on wrist)
Study: NCT01200485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasburicase
Description: Cycle 1: 3 mg/kg by vein on Day 1, plus as needed dosing (until day 5), during Cycle 1.~Cycle 2 Arm A: 0.15 mg/kg by vein on Day 1 of Cycle 2, plus as needed dosing (until day 5), during Cycle 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Arm B: 300 mg/day by vein, as standard of care, over 30 minutes each day on days 1-5 of cycle 2 in 21 day cycle.
Study: NCT02379273

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nucleus Hybrid L24 Implant
Description: Subjects have already been implanted with the Nucleus Hybrid L24 implant.
Study: NCT03710369

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The placebo pill was compounded by McDonalds Pharmacy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Sildenafil from Pfizer, compounded by McDonalds Pharmacy.
Study: NCT03062345

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single-User Virtual Reality Upper Extremity Therapy
Description: Virtual Reality games with the user as the only person required for participation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single-User Virtual Reality Upper Extremity Therapy
Description: Virtual Reality games with the user as the only person required for participation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-User Virtual Reality Upper Extremity Therapy
Description: Virtual reality games in which more than one user is required for participation. Users interact in the virtual environment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-User Virtual Reality Upper Extremity Therapy
Description: Virtual reality games in which more than one user is required for participation. Users interact in the virtual environment.
Study: NCT03004586

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 25-Gauge Needle
Description: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed by using a 25-gauge needle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 25-Gauge Needle
Description: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed by using a 25-gauge needle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 22-Gauge Needle
Description: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed by using a 25-gauge needle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 22-Gauge Needle
Description: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed by using a 25-gauge needle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA)
Description: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA)
Description: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed.
Study: NCT00025662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RFT5-SMPT-dgA
Description: A specific anti-interleukin-2 receptor immunotoxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isolex system
Description: CD34 selection/ T cell depletion used this system
Study: NCT04021082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerdulatinib
Description: Small molecule SYK/JAK kinase inhibitor in development for treatment of hematological malignancies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerdulatinib
Description: Small molecule SYK/JAK kinase inhibitor in development for treatment of hematological malignancies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerdulatinib
Description: Small molecule SYK/JAK kinase inhibitor in development for treatment of hematological malignancies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerdulatinib
Description: Small molecule SYK/JAK kinase inhibitor in development for treatment of hematological malignancies
Study: NCT02184299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study: NCT02569632

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals)
Description: All subjects will receive three doses of a Trumenba, a U.S.-licensed meningococcal vaccine. Each 0.5 mL dose contains 60 micrograms of each FHbp variant (total of 120 micrograms of protein), 0.018 mg of PS80 and 0.25 mg of Al³+ as AlPO4 in 10 mM histidine buffered saline at pH 6.0. Trumenba is administered as a three dose series (0.5 mL each) according to a 0-, 2-, and 6-month schedule.
Study: NCT02548676

Intervention type: DEVICE
Intervention: Optical angiography based on OCT
Description: This measurement will be obtained after the dilation of the pupil. Optical coherence tomography (OCT) is a non-invasive optical imaging modality enabling cross-sectional tomographic in vivo visualization of internal microstructure in biological systems. In ophthalmology OCT has become a standard device in visualizing the retina and is also considered a standard tool in the diagnosis of retinal disease. In optical angiography blood vessels contrasting against static tissue are visualized in a full depth resolved and label-free manner.

Intervention type: DEVICE
Intervention: Optical angiography based on OCT
Description: This measurement will be obtained after the dilation of the pupil. Optical coherence tomography (OCT) is a non-invasive optical imaging modality enabling cross-sectional tomographic in vivo visualization of internal microstructure in biological systems. In ophthalmology OCT has become a standard device in visualizing the retina and is also considered a standard tool in the diagnosis of retinal disease. In optical angiography blood vessels contrasting against static tissue are visualized in a full depth resolved and label-free manner.
Study: NCT02420405

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Routine gene testing
Description: For those diagnosed with nonsquamous NSCLC, routine gene testing including EGFR, ROS1 and ALK will be performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Next-generation sequencing
Description: For those diagnosed with nonsquamous NSCLC and have done routine gene testing, NGS will be perform on those that have adequate rest tissues.
Study: NCT00620633

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WT1-sensitized T cells
Description: Eligible patients who consent to enter this trial and for whom WT1 sensitized T cells have been generated in vitro, will receive a single dose of allogeneic WT1-sensitized T cells by bolus intravenous infusion. In this phase I trial, 6 dose levels of T cells will be evaluated, in sequential groups of 3 patients. Dose Escalation will be based on the incidence and severity of toxicities.
Study: NCT03575195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin 550mg orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control
Study: NCT03845023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD036 Dose 1
Description: AD036 Dose 1 oral capsule administered before sleep

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD036 Dose 1
Description: AD036 Dose 1 oral capsule administered before sleep
Study: NCT03710369

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sildenafil
Description: Sildenafil from Pfizer, compounded by McDonalds Pharmacy.
Study: NCT02109406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2115 Dose 1
Description: AZD 2115, Dose 1 administered as two inhalations BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD 2115, Dose 2
Description: AZD 2115, Dose 2 administered as two inhalations BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDI
Description: Placebo MDI administered as two inhalations BID
Study: NCT03845023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD036 Dose 2
Description: AD036 Dose 2 oral capsule administered before sleep

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD036 Dose 3
Description: AD036 Dose 3 oral capsule administered before sleep

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsule administered before sleep

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral capsule administered before sleep

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral capsule administered before sleep
Study: NCT01795859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-809
Description: SD-809 tablets are available in three dose strengths: 6, 9 and 12 mg, all of which are identical in size, shape and color (white).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-809
Description: SD-809 tablets are available in three dose strengths: 6, 9 and 12 mg, all of which are identical in size, shape and color (white).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets are identical in appearance to SD-809 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets are identical in appearance to SD-809 tablets.
Study: NCT04061070

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supplementation with mix of threalose plus polyphenols
Description: The patients will be treated with a mix of trehalose plus polyphenols for 60 days

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No Supplementation with mix of threalose plus polyphenols
Description: The patients will not be treated with a mix trehalose plus polyphenols for 60 days
Study: NCT01413022

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: flow cytometry
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04136309
Study: NCT03269513

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: The sessions will last two hours (one hour of physical exercise and the second time divided into nutritional counseling, postural, psychological and oral) with a frequency of three times a week.
Study: NCT02220218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin + Metformin Immediate Release (IR) Fixed Dose Combination (FDC)
Description: Canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin + Metformin Immediate Release (IR) Fixed Dose Combination (FDC)
Description: Canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin + Metformin Immediate Release (IR) Fixed Dose Combination (FDC)
Description: Canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin + Metformin Immediate Release (IR) Fixed Dose Combination (FDC)
Description: Canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Canagliflozin tablet 50 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Canagliflozin tablet 50 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Canagliflozin tablet 50 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Canagliflozin tablet 50 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin IR
Description: Metformin IR tablet 500 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin IR
Description: Metformin IR tablet 500 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin IR
Description: Metformin IR tablet 500 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin IR
Description: Metformin IR tablet 500 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.
Study: NCT01867970

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tool
Description: The It's LiFe! tool consists of three different elements:~1. the 3D accelerometer (Figure 7-8);~2. the application (app) on a Samsung Smartphone (Figure 6);~3. a web application and server called It's LiFe! online (powered by Sananet). The transmission of data from the accelerometer towards the app is via a Bluetooth connection. Every 15 minutes, or when the users press the refresh button, the Smartphone will connect to the accelerometer. The accelerometer should be within a 5 meter distance from the Smartphone. The transmission of data from the Smartphone towards the It's LiFe! server is via an internet connection. Therefore the Smartphone needs a SIM card with a data subscription.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management Support Program
Description: Consultations 1)The PN will increase awareness of the PA pattern, she will inform the patient about the health risks related to a sedentary lifestyle. Assessment of the PA level is done by completing the SQUASH questionnaire. The patient gets a leaflet with information about being active. 2)A day goal will be set in minutes a day, based on the results of the measurements of the first two weeks. The pre-measurement in condition 1 is an objective measurement by the tool and they are visible for the PN on the monitor portal of the It's LiFe! Server. The PN will encourage the patient to focus on goals that fit to the patient's preferences and to set up a SMART plan to reach personal goal. 3)The PN will discuss the results and barriers and facilitators related to physical activities. 4)The PN will discuss the results, behavior change and habits, with the patient.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management Support Program
Description: Consultations 1)The PN will increase awareness of the PA pattern, she will inform the patient about the health risks related to a sedentary lifestyle. Assessment of the PA level is done by completing the SQUASH questionnaire. The patient gets a leaflet with information about being active. 2)A day goal will be set in minutes a day, based on the results of the measurements of the first two weeks. The pre-measurement in condition 1 is an objective measurement by the tool and they are visible for the PN on the monitor portal of the It's LiFe! Server. The PN will encourage the patient to focus on goals that fit to the patient's preferences and to set up a SMART plan to reach personal goal. 3)The PN will discuss the results and barriers and facilitators related to physical activities. 4)The PN will discuss the results, behavior change and habits, with the patient.
Study: NCT04185922

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemopatch
Description: As stated in Hemopatch arm description
Study: NCT00279877

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kyphoplasty
Description: kyphoplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kyphoplasty
Description: kyphoplasty
Study: NCT03462537

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low level laser therapy
Description: Low level laser therapy protocol - The low level laser therapy protocol was performed in dorsal decubitus, with the head elevated at 45º. The electrodes were placed in line, in the abdominal region. The low level laser therapy device has a length of about 940nm, using 8 pads, which have 64 diodes, each one with 100mW. The duration of the application was established in 8 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Aerobic exercise protocol - 50 minutes of aerobic moderate-intensity exercise (45-55% of reserve heart rate) using Karvonen´s formula, performed on a cycloergometer. The duration of the exercise was divided into three parts: warm-up (from 0 to 5 minutes); body (from 5 to 45 minutes); and cooling (from 45 to 50 minutes). The entire protocol was monitored through the Polar® brand cardiofrequency and watch.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Aerobic exercise protocol - 50 minutes of aerobic moderate-intensity exercise (45-55% of reserve heart rate) using Karvonen´s formula, performed on a cycloergometer. The duration of the exercise was divided into three parts: warm-up (from 0 to 5 minutes); body (from 5 to 45 minutes); and cooling (from 45 to 50 minutes). The entire protocol was monitored through the Polar® brand cardiofrequency and watch.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low level laser therapy without power
Description: Low level laser therapy protocol - The low level laser therapy protocol was performed in dorsal decubitus, with the head elevated at 45º. The electrodes were placed in line, in the abdominal region. The low level laser therapy device has a length of about 940nm, using 8 pads, which have 64 diodes, each one with 100mW. The duration of the application was established in 8 minutes. In this group low level laser therapy device was switched off.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Low level laser therapy without power
Description: Low level laser therapy protocol - The low level laser therapy protocol was performed in dorsal decubitus, with the head elevated at 45º. The electrodes were placed in line, in the abdominal region. The low level laser therapy device has a length of about 940nm, using 8 pads, which have 64 diodes, each one with 100mW. The duration of the application was established in 8 minutes. In this group low level laser therapy device was switched off.
Study: NCT01940783

Intervention type: RADIATION
Group type: OTHER
Intervention: Cone Beam Computed Tomography (CBCT)
Description: Two postoperative CBCT scans, the first one on the day after cochlear implantation and the second after 3 months.

Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: One pre-operative (before cochlear implantation) MRI scan of the cochlea.
Study: NCT02658175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volanesorsen
Description: 300 mg volanesorsen administered via SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volanesorsen
Description: 300 mg volanesorsen administered via SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volanesorsen
Description: 300 mg volanesorsen administered via SC injection.
Study: NCT04124198

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-Modulated Radiation Therapy (IMRT)
Description: Accelerated or hyper-fractionated radiotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Concurrent weekly cisplatin 40 mg/sqm to fit patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nimorazole.
Description: Concurrent nimorazole

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transoral Robotic Surgery (TORS) with neck dissection
Description: Robotic-assisted resection of the primary oropharyngeal tumour and ipsilateral selected neck dissection of lymph node levels II-IV. Patients with a primary base of tongue cancer or with significant involvement of tongue base or the soft palate defined as above 1 cm, will be offered a bilateral neck dissection of levels II-IV.
Study: NCT00895388

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Structured Rehabilitation program
Description: Questionnaire send by post at 3, 6, 12, 18 and 24 months after operation
Study: NCT02554383

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-clavulanate
Description: Amoxicillin-clavulanate (90/6.4 mg/kg/d in 2 divided dosed for 10 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo made to match the study antibiotic given twice a day orally for 10 days